# Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose

> **NCT04715230** · PHASE2 · TERMINATED · sponsor: **InterveXion Therapeutics, LLC** · enrollment: 20 (actual)

## Conditions studied

- Methamphetamine Intoxication (Disorder)

## Interventions

- **BIOLOGICAL:** IXT-m200
- **DRUG:** Lorazepam
- **DRUG:** Haloperidol

## Key facts

- **NCT ID:** NCT04715230
- **Lead sponsor:** InterveXion Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-30
- **Primary completion:** 2022-10-05
- **Final completion:** 2022-11-14
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Sponsor decision based on slower than anticipated enrollment leading to fund exhaustion.
- **Last updated:** 2023-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04715230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04715230, "Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04715230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*